DenmarkDenmark

Santaris Pharma to raise EUR 12.5m

22.11.2007

Hamburg – Santaris Pharma A/S aims to close a Serie C financing round valued at a12.5 million in November/December. As the company announced during its pre-sentation in the framework of the BioEurope partnering conference held in Hamburg, Germany, from 12th to 14th October, negotiations with four investors are ongoing. Horsholm-based company Santaris Pharma was established in 2003 through the merger of the two biotech companies Pantheco A/S and Cureon A/S. The major focus of the company is to develop drug candidates based on Locked Nucleic Acid (LNA). One of the lead products (spc2996) is an Bcl-2 mRNA antagonist for the treatment of chronic lymphocytic leukaemia, with which an optimised second phase I/II began in Q1 2007. In 2006, the company raised a40 million.

DenmarkDenmark

07.03.2012

Bagsvaerd/Bangalore – Danish Novozymes A/S has begun a new collaboration with Indian Sea6 Energy. The companies will jointly develop enzymes to convert seaweed-based carbohydrates to sugar, which can then be fermented to produce...

DenmarkDenmark

06.03.2012

Prague/Turku/Copenhagen – Danish pharmaceutical company H. Lundbeck A/S yesterday unveiled clinical data on its potential blockbuster drug nalmefene at the 2012 European Congress of Psychiatry clinical in Prague. While Lundbeck...

DenmarkDenmark

05.03.2012

Copenhagen – With the in vitro proof of concept for an undisclosed antibody target, Genmab A/S has reached the second milestone in its collaboration with H. Lundbeck A/S. Genmab will now receive a €1m payment. Under the...

DenmarkDenmark

01.02.2012

Copenhagen/Bangalore – Biofuels need reliable sources of biomass. Novozymes now looks to the ocean to secure biomass. The Danish enzyme specialist announced an exploratory research agreement with Sea6 Energy from India. The...

DenmarkDenmark

02.01.2012

Copenhagen – Hellsinn Healthcare has successfully completed a phase Ib trial in Europe with Zealand Pharma’s GLP-2 (glucagone-like peptide 2) peptide antagonist Elsiglutide (ZP1846). The completion of the study, which was...

DenmarkDenmark

23.12.2011

Copenhagen - An alliance of giants will take a thorough look into biofuels for the maritime sector. The leading enzyme producer Novozymes will team up with parts of the Danish shipping industry, including the world’s largest...

DenmarkDenmark

17.12.2011

Copenhagen/Paris – Danish biopharma­ceuticals company Zealand Pharma A/S has received some positive news. Ever since French partner Sanofi Aventis submitted a marketing authorisation application for Lyxumia (lixisenatide) in...

DenmarkDenmark

07.11.2011

Copenhagen/Paris - The cooperation between Danish biopharmaceutical company Zealand Pharma and French drugmaker Sanofi has borne its first fruit. Sanofi has submitted a marketing authorisation application for Lyxumia...

DenmarkDenmark

01.10.2011

Copenhagen/Ingelheim – Danish HTS expert Nuevolution A/S has signed a license agreement with drugmaker Boeh­ringer Ingelheim (BI). The German pharma company will use Nuevolution’s proprietary Chemetics drug discovery technology...

DenmarkDenmark

25.08.2011

Bagsværd - Novo Nordisk is investing around €134m in a new corporate centre in the Copenhagen suburb Bagsværd. The new office premises will concentrate the top management and 1,100 administrative employees which are currently...

Displaying results 1 to 10 out of 194

1-10 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/news/messages-archive/archive-denmark/article/santaris-pharma-to-raise-eur-125m.html

Print Magazine

Event Video

All videos

Events

All Events

Stock list

All quotes

TOP

  • MOLOGEN7.65 EUR18.42%
  • BB BIOTECH150.50 EUR5.10%
  • CO.DON2.69 EUR4.26%

FLOP

  • 4SC0.80 EUR-8.05%
  • CYTOS0.16 CHF-5.88%
  • WILEX2.15 EUR-4.44%

TOP

  • BIOFRONTERA2.85 EUR29.5%
  • ADDEX3.30 CHF6.5%
  • BB BIOTECH150.50 EUR2.6%

FLOP

  • CYTOS0.16 CHF-33.3%
  • 4SC0.80 EUR-31.6%
  • PAION2.20 EUR-27.9%

TOP

  • SANTHERA81.90 CHF2072.4%
  • CO.DON2.69 EUR174.5%
  • PAION2.20 EUR144.4%

FLOP

  • CYTOS0.16 CHF-95.9%
  • 4SC0.80 EUR-54.8%
  • THERAMETRICS0.07 CHF-50.0%

No liability assumed, Date: 20.10.2014


Current issue

All issues

Product of the week

Products